ABIONYX Pharma is expanding rapidly following its General Meeting

ABIONYX Pharma, a biopharmaceutical company, announced a significant expansion following its Combined General Meeting. All proposed resolutions were adopted, paving the way for new ambitions. Among the flagship projects is the launch of a pivotal clinical phase for CER-001 in sepsis, scheduled before the end of 2026, with results expected in the first half of 2028.

The company has secured €33 million to guarantee the development of its strategic programs, including the approval of CER-001 for the LCAT deficit. This phase is accompanied by a focus on optimizing their proprietary scientific platform based on apoA-I, and developing new industrial partnerships.